Skip to content
Saturday, March 15, 2025
GLP-1 Watch
All the latest news and updates about GLP-1 Drugs
Search
Search
Privacy Policy
The Evolving Landscape of GLP-1 Drugs: Innovations, Market Trends, and Health Implications
Home
2025
March
7
J&J drops Phase III MDD programme due to lack of efficacy
GLP-1 News
J&J drops Phase III MDD programme due to lack of efficacy
March 7, 2025
admin
J&J’s news about aticaprant’s Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.
Post navigation
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance – U.S. News & World Report
UK’s pricing watchdog rejects Alzheimer treatments for the second time